

Cat No. 23-F18

EHNA Hydrochloride


10 mg



For research purposes only

EHNA Hydrochloride is a reversible adenosine deaminase inhibitor that selectively inhibits the cGMP-specific phosphodiesterase (PDE2). At a 10 μ M concentration, EHNA has been shown to effectively and reversibly block the differentiation and maintain the pluripotency of the hES cell line SA121 in feeder-free cultures without exogenously added FGF for up to 30 passages. EHNA has also been used to study the cardioprotective and neuroprotective efforts during ischemia and in the study of cAMP/cGMP signaling.

TECHNICAL INFORMATION



Other Names: 6-amino-b-hexyl-a-methyl-9H-purine-9-ethanol, dihydrochloride

Chemical Formula: C₁₄H₂₃N₅O • HCl

CAS Number: 58337-38-5

Molecular Weight: 313.8

Purity: >98%

Appearance: a crystalline solid

Solubility: DMSO

STORAGE AND HANDLING

Storage: Store at 4°C and protected from light. Following reconstitution, store aliquots at -20°C.

Stability: Stock solutions stable at -20°C for up to 2 years.

Shipping Conditions: Shipped at room temperature.

PRODUCT USE

Soluble in DMSO. If precipitate is observed, vortex for 5 minutes. For most cells, the maximum tolerance to DMSO is less than 0.5%.

REFERENCES

1. Burton et al. (2010) Erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) blocks differentiation and maintains the expression of pluripotency markers in human embryonic stem cells. *Biochem J.* 432(3): 575-84.
2. Lorbar et al. (1999) Effect of aging on myocardial adenosine production, adenosine uptake and adenosine kinase activity in rats. *J Mol Cell Cardio.* 31(2):401-12.
3. Verde et al. (1999) Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca²⁺ current in rat ventricular myocytes. *Br J Pharmacol.* 127(1):65-74.